검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Opdualag |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Cutaneous Melanoma |
Overview Indication | Childhood Cancer; Childhood Solid Tumor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | and clinical trials of relatlimab and a brief overview of immune checkpoint drugs currently used for the treatment of melanoma |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report.. Immune checkpoint inhibitors (ICIs) have transformed the management of metastatic melanoma, providing durable survival benefits in a subset of patients. However, their use is associated with immune-related adverse events (irAEs), which may be unpr… |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT05002569 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Opdualag |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Cutaneous Melanoma |
Overview Indication | Childhood Cancer; Childhood Solid Tumor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | and clinical trials of relatlimab and a brief overview of immune checkpoint drugs currently used for the treatment of melanoma |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report.. Immune checkpoint inhibitors (ICIs) have transformed the management of metastatic melanoma, providing durable survival benefits in a subset of patients. However, their use is associated with immune-related adverse events (irAEs), which may be unpr… |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT05002569 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교